1. Home
  2. VCEL vs REVBW Comparison

VCEL vs REVBW Comparison

Compare VCEL & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • REVBW
  • Stock Information
  • Founded
  • VCEL 1989
  • REVBW N/A
  • Country
  • VCEL United States
  • REVBW United States
  • Employees
  • VCEL N/A
  • REVBW 9
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • REVBW Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCEL Health Care
  • REVBW Health Care
  • Exchange
  • VCEL Nasdaq
  • REVBW Nasdaq
  • Market Cap
  • VCEL N/A
  • REVBW N/A
  • IPO Year
  • VCEL 1997
  • REVBW 2020
  • Fundamental
  • Price
  • VCEL $56.81
  • REVBW $0.02
  • Analyst Decision
  • VCEL Strong Buy
  • REVBW
  • Analyst Count
  • VCEL 7
  • REVBW 0
  • Target Price
  • VCEL $63.29
  • REVBW N/A
  • AVG Volume (30 Days)
  • VCEL 396.0K
  • REVBW N/A
  • Earning Date
  • VCEL 02-27-2025
  • REVBW N/A
  • Dividend Yield
  • VCEL N/A
  • REVBW N/A
  • EPS Growth
  • VCEL N/A
  • REVBW N/A
  • EPS
  • VCEL 0.07
  • REVBW N/A
  • Revenue
  • VCEL $226,844,000.00
  • REVBW N/A
  • Revenue This Year
  • VCEL $23.08
  • REVBW N/A
  • Revenue Next Year
  • VCEL $21.58
  • REVBW N/A
  • P/E Ratio
  • VCEL $755.87
  • REVBW N/A
  • Revenue Growth
  • VCEL 22.48
  • REVBW N/A
  • 52 Week Low
  • VCEL $39.12
  • REVBW N/A
  • 52 Week High
  • VCEL $63.00
  • REVBW N/A
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 44.92
  • REVBW N/A
  • Support Level
  • VCEL $54.45
  • REVBW N/A
  • Resistance Level
  • VCEL $63.00
  • REVBW N/A
  • Average True Range (ATR)
  • VCEL 2.29
  • REVBW 0.00
  • MACD
  • VCEL -0.43
  • REVBW 0.00
  • Stochastic Oscillator
  • VCEL 27.60
  • REVBW 0.00

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: